Immune globulin improved yield - Takeda
Alternative Names: BAX 1415; IG yield improvementLatest Information Update: 13 Jan 2022
At a glance
- Originator Baxalta
- Developer Takeda
- Class Anti-infectives; Anti-inflammatories; Antibacterials; Antidementias; Antifibrotics; Antivirals; Eye disorder therapies; Immunoglobulins; Immunoproteins; Polyethylene glycols; Serum globulins; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Immunological disorders
Most Recent Events
- 28 Jun 2019 No recent reports of development identified for preclinical development in Immunological-disorders in USA (Parenteral, Injection)
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 03 Jun 2016 Baxalta has been acquired and merged into Shire